Novartis shareholder urges board overhaul after share plunge tied to trial setbacks

A prominent Novartis investor has publicly called for a revamp of the company’s board, arguing that stronger governance is needed after the stock experienced a record decline.

The demand was voiced by David Samra of Artisan Partner, who told Reuters the back‑to‑back trial disappointments have shaken investor confidence and warrant changes at the board level.

The sharp fall in Novartis shares underscores the market’s reaction to the setbacks and adds pressure on the drugmaker to address both its clinical pipeline and its leadership structure.